Accordingly, ADAR1 inhibitors hold immense promise as effective therapeutics for cancer treatment,15 given their potential to disrupt two distinct pro-oncogenic functions of ADAR1: suppression of IFN signaling, resulting in a diminished tumor ICB response (ADAR1p150 function), and the maintenance of telomere stability in telomerase-reactivated cancers (ADAR1p110 function). Here, IFNA1 is linked to neoplasm.